TIDMOPTI
RNS Number : 9723I
OptiBiotix Health PLC
27 March 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Scientific and commercial update
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, provides the following scientific and commercial
update on its technology and products. The Company is developing
technology and products in the microbiome space, a market growing
at 22.3% per year, and described by health experts as "healthcare's
most promising and lucrative frontier" (Markets and Markets).
The Company is building value within each of its three divisions
leveraging the uniqueness of its technology to commercialise food
ingredients and products so that each division becomes profitable
and self-sustainable. Per Rehne is leading the commercialisation of
LP(LDL) (R), whilst Christina Wood is leading the commercialisation
of SlimBiome(R). The overall aim is for divisions to become
separate profitable legal entities which, if appropriate, may be
taken to the public markets as a separate listing. The following
sections provide a scientific and commercial update for each
division.
OptiBiome(R) (SlimBiome(R), CardioBiome, ImmunoBiome,
WellBiome(R) and PsychoBiome)
Christina Wood has made strong progress since commencing her
role as Sales and Marketing Director in March 2017. Christina has
been working with manufacturers, application developers, and
retailers to expand the range of application opportunities.
SlimBiome(R) has now been developed with a number of partners into
breaded products, biscuits, dairy, gummies (children's products),
muesli pots, porridge pots, healthy snacks such as yoghurt coated
fruits, and a range of cereals in puff, flakes, and crisp format.
As we formalise our relationship with partners for other
applications we anticipate a growing deal pipeline.
This creates a wide range of revenue generating opportunities
and the potential to either extend the GoFigure range of online
products or create a 'health and wellbeing' own label brand for one
of the major supermarkets. Late stage discussion are currently
ongoing with three supermarkets.
The Company is extending its OptiBiome(R) range beyond weight
management (SlimBiome(R)), to include cardiovascular health
(CardioBiome(R)), immune health (ImmunoBiome(R)), cognitive health
(PsychoBiome), and general health (WellBiome(R)) which will further
extend the range of product opportunities.
LP(LDL) (R)
Per Rehne has been working with manufacturers, formulation and
distribution partners to develop around 30 formulations of LP(LDL)
(R) which have the science, cost structure, and synergistic mode of
action to create a wide product range (consistent with our intel
inside model). This approach allows OptiBiotix to present product
solutions to consumer health, pharmaceutical and retail companies
which give us multiple revenue streams from ingredient sales, white
label and own branded products. Investors will have seen from
recent RNS releases the evolution from small privatelyowned pharma
companies, who are quicker to execute agreements, to larger deals
with GBP100m plus revenue companies like Fine Foods and Gallenicum.
This division has a broad deal pipeline and we anticipate
announcing further deals in the forthcoming months both for LP(LDL)
(R) and new application areas.
The science behind OptiBiotix's LP(LDL) (R) product won best
scientific publication at ProBiota 2017 and 2018. These awards
raise OptiBiotix's profile and reputation, attract commercial
interest in our technology and products, and provide the scientific
evidence for sales and marketing literature in support of product
commercialisation.
Online Store
The company is building its product portfolio with partners and
is developing an online store to create a shop window for its
technologies and products. This will sell GoFigure products, the
wider range of SlimBiome products, and LP(LDL) (R) formulations,
creating an additional revenue stream and the opportunity for
direct market feedback from its customers. We expect this
transition to be completed by the end of April with new product
offerings being added to the online store on an ongoing basis. This
is all part of a gradual transition of OptiBiotix from a research
and development company to a commercial business. The overall aim
is to build revenues within each division to between GBP5m-GBP10m
per annum over the forthcoming years.
OptiBiotics(R), Microbiome Modulators and SweetBiotix(R)
The Company has made significant progress in its scientific
programmes to develop compounds which modify the human microbiome
to prevent, manage and treat disease, and create natural high
intensity sweeteners and sweet healthy fibres (SweetBiotix(R)).
Given the international interest in the microbiome and natural
alternatives to sugar, the Company has carried out a total of five
successful human taste studies on its SweetBiotix(R) product
development programmes.
These studies have created interest from a number of corporates
with expertise in the manufacture and commercialisation of
speciality ingredients and/or consumer products. In March 2018 the
Company met up with teams of scientists and senior executives from
each of these companies. It was clear from our meetings that
OptiBiotix are global leaders in targeted microbiome modulation and
sweet prebiotics/fibres.
We are pleased to report that every company has expressed strong
interest in partnering or investing in OptiBiotix to access our
technology. This high level of interest now needs to be turned into
tangible deals which, subject to any corporate confidentiality
clauses, we can disclose to the market. Investors should be
cautioned that negotiations with large corporate partners is a
two-way process which has to fit into a corporate process and
timescale and are often subject to stringent confidentiality
clauses. However, it's clear that OptiBiotix is in the right space
(microbiome, sweet fibres), and has a structured approach to
development appealing to corporate partners, allowing it to attract
the high level of interest from these global brands.
Stephen O'Hara, CEO of OptiBiotix, commented: "The Company
believes it is making strong scientific and commercial progress
across all its technology and product platforms. This has led to a
number of deals with each division building a rich deal pipeline,
which if successfully concluded, will lead to significant revenues
in the months and years ahead. Industry interest is coming from
national retailers and global corporates which have potential for
significant upside given the scale of their market reach. We remain
on track with our strategy of building multiple revenue streams
from both consumer and pharmaceutical products across all our
technology platforms."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP (Nomad) Tel: 020 7213
0880
Liam Murray
finnCap (Broker) Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Abigail Wayne (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEALDKASDPEFF
(END) Dow Jones Newswires
March 27, 2018 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024